Eye　movement　disorder　(EMD)　is　a　significant　cause　of　visual　impairment　and　disruption　of　daily　activities.　Drug-induced　EMD　is　an　underrecognized　but　critical　risk　factor　for　patients.　This　study　aimed　to　explore　the　relationship　between　medications　and　EMD　using　real-world　data　to　improve　patient　safety　and　clinical　decision-making.　A　total　of　6,158　reports　of　drug-induced　EMD,　involving　1,834　unique　drugs,　were　analyzed　from　the　FDA　Adverse　Event　Reporting　System　(FAERS)　spanning　Q1　2004　to　Q4　2024.　Disproportionality　analysis　revealed　30　drugs　with　significant　associations　with　EMD,　primarily　within　the　central　nervous　system　drug　class,　including　antiseizure　medications　(vigabatrin,　topiramate),　antipsychotics　(aripiprazole,　risperidone),　and　antidepressants　(sertraline,　venlafaxine).　The　highest　risks　were　observed　with　zonisamide　(BCPNN　=　3.03),　vigabatrin　(BCPNN　=　2.82),　and　tiagabine　(BCPNN　=　2.79).　Acyclovir　and　donepezil　had　the　shortest　onset　times　(median:　2　days).　EMD-related　adverse　events　were　most　commonly　reported　in　middle-aged　and　elderly　women　(55.3%),　and　the　number　of　cases　has　been　steadily　increasing　over　time.　This　study　provides　essential　pharmacovigilance　insights,　identifying　high-risk　medications　and　demographic　factors　associated　with　drug-induced　EMD,　which　can　inform　clinical　practice　and　optimize　patient　care.